&w=3840&q=100)
Spunweb Nonwoven IPO booked 251x; check allotment status, GMP, listing date
According to data from the National Stock Exchange (NSE), Spunweb Nonwoven IPO was booked over 251 times, receiving bids for 1.06 trillion shares against 4.22 million shares on offer.
Here's how to check Spunweb Nonwoven IPO allotment status
Investors can check their allotment status for the Spunweb Nonwoven IPO on the official websites of the NSE and MUFG Intime India, the registrar of the issue. Investors can also use the links below to check the Spunweb Nonwoven IPO allotment status:
Spunweb Nonwoven IPO grey market premium (GMP)
On July 17, the unlisted shares of Spunweb Nonwoven were trading at ₹130 per share in the grey market, commanding a premium of ₹34 or 35.42 per cent, according to sources tracking unofficial market activity.
Spunweb Nonwoven IPO details
The SME offering, valued at around ₹60.98 crore, comprises an entirely fresh issue of 6.35 million equity shares. Spunweb Nonwoven IPO does not include any offer-for-sale (OFS) component.
The public issue was open for subscription from Monday, July 14, 2025, to Wednesday, July 16, 2025. It was priced in the range of ₹91-96 per share. The company has fixed the lot size of 1,200 shares. Vivro Financial Services is the sole book-running lead manager for the IPO.
According to the red herring prospectus (RHP), Spunweb Nonwoven plans to utilise the proceeds from the IPO to fund the company's working capital requirements, investment in wholly owned subsidiary, SIPL, and for general corporate purposes.
About Spunweb Nonwoven
Incorporated in 2015, Spunweb Nonwoven is a manufacturer and supplier of non-woven fabrics, primarily used for applications like doormats, bags, carpets, and tarpaulins. The company manufactures nonwoven fabric, laminated, and UV-treated nonwoven fabric. It also operates state-of-the-art testing facilities, including Universal Tensile Testing and Rewet Properties Testing.
Spunweb Nonwoven exports its products to North America, Europe, and the Middle East. The company generates over two-thirds of its revenue from the hygiene sector, and the remaining portion from applications in medical, packaging, agriculture, and construction industries.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
14 minutes ago
- Mint
Anthem Biosciences share price gains after strong listing. Should you buy, sell of hold the stock?
Anthem Biosciences share price made a stellar debut in the Indian stock market today after its initial public offering (IPO) received strong demand. Anthem Biosciences shares were listed at ₹ 723.05 apiece on the NSE, a premium of 26.85% to the issue price of ₹ 570 per share. On BSE, Anthem Biosciences share price opened at ₹ 723.10 apiece, higher by 26.86% from the IPO price. Anthem Biosciences is a manufacturer of specialized fermentation-based APIs and its IPO was heavily oversubscribed. Anthem Biosciences IPO listing date was today, 21 July 2025. Anthem Biosciences IPO listing was in line with the Street estimates as indicated by the grey market premium (GMP). Anthem Biosciences IPO GMP today ahead of the listing and analysts had signalled a strong debut of shares. Here's what investors should do after Anthem Biosciences share listing today. Mahesh M. Ojha, AVP - Research & Business Development at Hensex Securities Pvt. Ltd. advises short-term investors who were allotted shares to consider booking partial profits as he believes over 25% gain at listing is substantial, and booking gains allows for risk management. 'Long-term investors should focus on the company's growth roadmap. Anthem has strong fundamentals, but future performance will depend on margin sustainability, innovation pipeline, and global client growth. For investors who missed the IPO, it would be wise to wait for a few trading sessions. Once the stock stabilizes, it may offer a better entry point based on earnings visibility and peer comparison,' Ojha said. According to Prashanth Tapse, Sr Vp Research & Research Analyst at Mehta Equities Ltd, Anthem Biosciences made a healthy debut, broadly in line with expectations, reflecting strong investor appetite. 'While post-listing valuations may appear premium, we believe these are justified by the company's strong fundamentals, differentiated capabilities, and the sector's long-term growth visibility. The ability to consistently deliver earnings growth, in line with street expectations, further supports its valuation,' Tapse said. Hence, looking at its all financial as well as sectorial, he recommends investors to 'Hold' Anthem Biosciences shares for long-term perspective. 'For long-term investors, Anthem offers a strong structural story in a booming Indian CRDMO segment, justifying the listing. Short term we foresee ₹ 900 as target while long term investors can hold it for ₹ 1,000 and above. Non allottees wait for some volatility to settle in price and in any case if the stock is available around ₹ 650-680, can be considered a good range to accumulate with long term vision,' Tapse said. Shivani Nyati, Head of Wealth at Swastika Investmart Ltd. recommends investors to secure partial profits and retain the remainder with a stop-loss set at ₹ 650. Anthem Biosciences IPO was open from July 14 to July 16. The IPO was subscribed 63.86 times in total, as per the NSE subscription data. The retail portion was booked 5.64 times, while the Non Institutional Investors (NII) segment was subscribed 42.36 times. The Qualified Institutional Buyers (QIBs) category received 182.65 times subscription. At 12:25 PM, Anthem Biosciences share price was trading at ₹ 728.90 apiece on the BSE, up by 0.80% from its listing price, and up 27.88% from its issue price. Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.
Business Standard
20 minutes ago
- Business Standard
NSE SME Spunweb Nonwoven weaves a winning debut
Shares of Spunweb Nonwoven was trading at Rs 158.55 on the NSE, a premium of 65.16% compared with the issue price of Rs 96. The scrip was listed at Rs 151, a premium of 57.29% compared with the initial public offer (IPO) price. The stock is currently frozen at its upper limit of 5% over its listing price. The counter hit a high of Rs 158.55 and a low of Rs 151. About 25.90 lakh shares of the company changed hands at the counter. Spunweb Nonwoven's IPO was subscribed 233.35 times. The issue opened for bidding on 14 July 2025 and it closed on 16 July 2025. The price band of the IPO was set at Rs 90 to Rs 96 per share. The IPO comprised fresh issue of 45,48,000 equity shares. The company intends to utilize the net proceeds for funding its working capital requirements, investing in its wholly-owned subsidiary, SIPL, for funding its working capital requirements, repayment (in full or in part) of certain borrowings availed by the company and for general corporate purposes. Ahead of the Spunweb Nonwoven on 11 July 2025, raised Rs 17.31 crore from anchor investors. The board has allotted 18.03 lakh shares at Rs 96 per share to 8 anchor investors. Spunweb Nonwoven is engaged in the manufacturing of polypropylene spunbond nonwoven fabrics, primarily used in industries such as hygiene, healthcare, packaging, agriculture, and others (including roofing and construction, industrial, and home furnishing). Its product portfolio consists of hydrophobic nonwoven fabric, hydrophilic nonwoven fabric, super-soft nonwoven fabric, UV-treated fabric, antistatic nonwoven fabric, and flame-retardant (FR) treated fabric. As of 31 May 2025, the company had 199 employees on its payroll and 51 employees on its subsidiary payroll and engaged more than 30 contract labourers at the manufacturing facility. The company recorded revenue from operations of Rs 226.35 crore and net profit of Rs 10.79 crore for the period ended 31 March 2025.
Mint
27 minutes ago
- Mint
Anthem Biosciences shares make robust debut, list at ₹723.05 on NSE, up 26.85% from IPO price
Anthem Biosciences IPO listing: Shares of Anthem Biosciences made a stellar debut on the bourses on Monday, July 21, listing at ₹ 723.05 on NSE, a premium of 26.85 percent over its IPO price of ₹ 570. Meanwhile, on BSE, it listed at ₹ 723.10, up 26.86 percent from issue price. The initial public offering (IPO), with a total issue size of ₹ 3,395.79 crore, was open for bidding from July 14 to July 16. The offering received an robust response from investors, closing with a subscription of 67.42 times. The IPO attracted bids for 281.49 crore shares compared to the 4.17 crore shares on offer. The retail investor category was subscribed 5.98 times while the non-institutional investor (NII) segment witnessed 44.70 times subscription. Meanwhile, the qualified institutional buyer (QIB) portion was bid the most, 192.80 times. Meanwhile, the employee quota was booked 6.99 times in this period. The IPO was entirely an offer for sale of 5.96 crore shares with no offer-for-sale. The lot size for the IPO was fixed at 26 shares, with the minimum investment for retail investors set at ₹ 14,040. The issue also included a reservation of up to 1,58,653 shares for employees offered at a discount of ₹ 50.00 to the issue price. As the IPO is completely an OFS, the company will not acquire any funds from the offering, and the proceeds will be directed to the selling shareholders. Ahead of the public offering, the company successfully raised ₹ 1,016 crore from anchor investors on July 11. JM Financial Limited was the book-running lead manager for the issue, while Kfin Technologies was its registrar. Founded in 2006, Anthem Biosciences Limited is a technology-led, innovation-centric Contract Research, Development, and Manufacturing Organization (CRDMO) offering end-to-end services across drug discovery, development, and manufacturing. The company caters to a broad global clientele, ranging from emerging biotech startups to leading pharmaceutical giants. Anthem Biosciences is engaged in the production of niche, fermentation-based active pharmaceutical ingredients (APIs), including probiotics, enzymes, peptides, nutritional ingredients, vitamin analogues, and biosimilars. The company's listed peers are Syngene International Ltd (with a P/E of 51.54), Sai Life Sciences Ltd (with a P/E of 92.18), Cohance Lifesciences Ltd (with a P/E of 97.29), and Divi's Laboratories Ltd (with a P/E of 83.22). In the financial year 2024-25, the company reported a 30 percent year-on-year growth in revenue from operations, which rose to ₹ 1,844 crore from ₹ 1,419 crore in FY24. Its profit after tax stood at ₹ 451 crore for the year ended March 31, 2025, reflecting a 23 percent increase compared to the previous year.
